Status:
RECRUITING
Three miRNA Signatures in Glioma: From Molecular Mechanisms to Potential Clinical Application
Lead Sponsor:
Regina Elena Cancer Institute
Collaborating Sponsors:
University of Roma La Sapienza
San Camillo Hospital, Rome
Conditions:
Glioma
Eligibility:
All Genders
Brief Summary
Individual overexpression of the three miRNAs negatively affects cell viability and proliferation mainly in grade III IDH-wild type cells, while in higher grade cells, the effect is more pronounced wh...
Detailed Description
Decipher the impact and functional role of the signature formed by miR-1-3p, miR-26a-1-3p and miR-487b-3p on glioma biology. The functional role of the miRNAs of the signature will be assessed with ga...
Eligibility Criteria
Inclusion
- histological diagnosis of glioma;
- no concomitant primary tumor;
- no metastatic disease;
- availability of surgical material/tissue;
- written informed consent.
Exclusion
- histological diagnosis of non-glial tumor;
- patients with concomitant other solid tumors;
- metastatic disease;
- no surgical material/tissue available;
- HIV seropositivity.
Key Trial Info
Start Date :
January 17 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 17 2027
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06883214
Start Date
January 17 2023
End Date
January 17 2027
Last Update
March 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
"Regina Elena" National Cancer Institute
Rome, Italy, 00144